chufangao/CTO huggingface dataset:
Clinical trial NCT04146896: Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Sponsor: Aptinyx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 228.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-12
Primary completion date: 2022-02-23
Completion date: 2022-02-23
Plan to share individual participant data: NO
Clinical trial NCT05286255: Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
Official title: Safety and Tolerability of Allogeneic Umbilical Cord Derived Mesenchymal Stromal Cells (UC-MSCs) to Limit COVID Associated ComplicatioNs: An Open Label, Phase 1 Study in Hospitalized Patients (SAMPSON-1)
Acronym: SAMPSON-1
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-10-01
Primary completion date: 2024-10-01
Completion date: 2024-10-01
Plan to share individual participant data: YES
IPD sharing description: Biosamples are stored in the MUSC COVID-19 Biorepository
IPD time frame: Samples and Matching Participant data will be shared at the end of the study
IPD access criteria: Email to strangec@musc.edu
Clinical trial NCT04403243: COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
Official title: COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
Acronym: COLORIT
Sponsor: Lomonosov Moscow State University Medical Research and Educational Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-05-08
Primary completion date: 2020-07-22
Completion date: 2020-08-23
Plan to share individual participant data: YES
IPD time frame: 4 month
IPD access criteria: Medical professionals By the request
Clinical trial NCT04844086: RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Official title: Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients With Advanced Lymphoid Malignancies
Sponsor: Eden BioCell Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: CAR-T manufacturing technology can not meet the dose requirement for clinical patients.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-02
Primary completion date: 2022-05-12
Completion date: 2022-05-12
Plan to share individual participant data: NO
Clinical trial NCT02563002: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Official title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 307.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-30
Primary completion date: 2021-02-19
Completion date: 2023-07-17
Baseline population: All randomized participants
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04466215: Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Official title: Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Sponsor: The Scripps Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-15
Primary completion date: 2022-04-15
Completion date: 2022-06-07
Plan to share individual participant data: NO
Clinical trial NCT03452488: A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
Official title: Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability
Acronym: SARA-INT
Sponsor: Biophytis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 233.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-02-07
Primary completion date: 2020-04-26
Completion date: 2020-04-26
Baseline population: One participant randomized but not treated with 175 mg BIO101.
Limitations and caveats: Due to the coronavirus disease 2019 (COVID-19) outbreak, the implementation of the clinical protocol was affected, including but not limited to the scheduled site visit for safety and/or efficacy, site visits for monitoring, investigational product delivery, collection of adverse events (AEs) and concomitant medications. This led to \>50% loss of efficacy data for the primary endpoint and other performance assessments.
Plan to share individual participant data: NO
Clinical trial NCT04791319: A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Official title: A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Acronym: GENESIS
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Premature Termination due to Interim Analysis (100 patients at Week 16) meeting futility.
Enrollment: 199.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-05-03
Primary completion date: 2022-02-02
Completion date: 2022-03-31
Baseline population: The full analysis set (FAS) included all participants who were randomized at Week 0 and received at least 1 dose of study intervention.
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04375397: Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Official title: IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)
Acronym: iNSPIRE
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-06
Primary completion date: 2021-05-10
Completion date: 2021-06-08
Baseline population: Full Analysis Set (FAS): all randomized participants who received at least 1 dose of study drug
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu
Clinical trial NCT05033080: A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Official title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 435.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-14
Primary completion date: 2023-05-12
Completion date: 2023-11-21
Baseline population: All randomized participants who carry the intended CFTR genotype and received at least 1 dose of study drug in a study.
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT02715505: Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)
Official title: A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: This study was cancelled with no patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-10
Primary completion date: 2020-05-18
Completion date: 2020-05-18
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03931915: Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
Official title: Phase III Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
Sponsor: ASKA Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 335.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-08
Primary completion date: 2020-06-12
Completion date: 2020-09-28
Plan to share individual participant data: NO
Clinical trial NCT04094584: Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder
Official title: Feasibility of Emergency Department Initiated Extended-Release Naltrexone and Case Management Services for the Treatment of Alcohol Use Disorder
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: 12 month follow up data not collected due to pandemic disruptions
Enrollment: 179.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-14
Primary completion date: 2022-05-01
Completion date: 2022-05-01
Plan to share individual participant data: NO
Clinical trial NCT04369742: Treating COVID-19 With Hydroxychloroquine (TEACH)
Official title: Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Investigator decision
Enrollment: 128.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-15
Primary completion date: 2021-04-01
Completion date: 2021-04-01
Plan to share individual participant data: YES
IPD sharing description: The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: \[contact information for PI or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: Requests should be directed to mark.mulligan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT04999098: Echinaforce COVID-19 Shedding Study
Official title: Randomized, Controlled, 3-arm, Open, Prospective Clinical Trial to Assess Antiviral Properties of Echinacea Reducing Oropharyngeal Concentration and Infectivity of SARS-CoV-2: The Shedding Study
Sponsor: A. Vogel AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: insufficient recruitment
Enrollment: 40.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-15
Primary completion date: 2023-05-15
Completion date: 2023-08-15
Plan to share individual participant data: UNDECIDED
IPD sharing description: There is no plan yet
Clinical trial NCT02008357: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Official title: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Acronym: A4
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1169.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-02-28
Primary completion date: 2022-12-27
Completion date: 2023-06-08
Baseline population: All randomized participants.
Limitations and caveats: Per protocol and SAP, delayed-start analyses were not conducted because no treatment difference was observed at the end of the double-blind (placebo-controlled) period. Hence, data were not evaluated for outcome measure analyses (week 336), but safety data were analyzed for open-label extension period.
Clinical trial NCT04598269: Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Official title: A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Sponsor: Aclaris Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2021-04-08
Completion date: 2021-04-22
Baseline population: All participants who received 1 dose of study drug.
Clinical trial NCT05178862: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Official title: A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)
Acronym: MARIO
Sponsor: Scynexis, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: During a review of manufacturing equipment and cleaning activities at a supplier that manufactured study drug for this study, SCYNEXIS was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance.
Enrollment: 220.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2022-08-03
Primary completion date: 2024-06-30
Completion date: 2024-08-31
Clinical trial NCT03993236: Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke
Official title: Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin for Target LDL-C Goal Achievement in Patients With Recent Ischemic Stroke: a Randomized Clinical Trial
Sponsor: Inje University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 584.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-09
Primary completion date: 2021-09-27
Completion date: 2021-09-27
Plan to share individual participant data: NO
Clinical trial NCT04778059: Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
Official title: Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection
Sponsor: US Biotest, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Unable to enroll in timely manner due to nature of COVID
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-27
Primary completion date: 2022-05-10
Completion date: 2022-05-10
Baseline population: All enrolled subjects who received a USB002 or Placebo infusion were included in the analysis population for all outcomes analyzed.
Limitations and caveats: Per protocol, this clinical trial was designed to include two parts (Part 1 - dose escalation phase; Part 2 - dose expansion phase). Part 2 did not proceed due to enrolment difficulty. Sponsor encountered challenges in finding subjects that met study eligibility criteria. This was likely due to the role COVID-19 vaccinations played, limiting the spread and hospitalizations of COVID-19 patients. Sponsor terminated the trial early, when 21 subjects (all Part 1) had been enrolled.
Plan to share individual participant data: NO
Clinical trial NCT03928808: Fecal Microbiota Transplantation (FMT) in Treatment of Severe and Enduring Anorexia Nervosa
Official title: Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Severe and Enduring Anorexia Nervosa (SE-AN)
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Withdrawn due to covid-19 protocols on inpatient eating disorders unit.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-04-01
Primary completion date: 2024-03-31
Completion date: 2024-09-30
Plan to share individual participant data: YES
IPD sharing description: Deidentified individual participant data (IPD) will be made available by controlled access. Qualified researchers with documented evidence of ethical approval and a clear research and statistical analysis plan will be given access through a secure file transfer protocol (FTP) site. Data to be shared include diagnostic information, age, non-identifying demographic data (including BMI and other anthropometric measures), psychometric, and sequence data along with a data dictionary.
IPD time frame: 6 months after publication of the primary publication
IPD access criteria: To qualified applicants with documented IRB approval and analytic plan. A Data Use Agreement must be executed with UNC prior to actual sharing of data.
Clinical trial NCT04509726: EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma
Official title: Single-Arm Trial of EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Head and Neck Carcinoma Metastatic/Refractory Nasopharyngeal Carcinoma
Sponsor: Xinqiao Hospital of Chongqing (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Scheduled Pause
Enrollment: 20.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2023-03-01
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03963102: Duration of Ameluz Application in Acral Actinic Keratoses Response
Official title: A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses
Sponsor: Royal Cornwall Hospitals Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of appropriate personnel. Dr Xie abroad on other research, current PI Dr John Frewen not at main centre, no other available PI identified. Study suspended.
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-30
Primary completion date: 2024-03-31
Completion date: 2024-03-31
Plan to share individual participant data: NO
IPD sharing description: Please contact study coordinators to see if non-patient identifiable information can be release.
Clinical trial NCT05044936: Topical Cannabidiol Cream and Post-exercise Recovery
Official title: The Effects of Topical Cannabidiol Cream on Post-exercise Recovery
Sponsor: University of New Mexico (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: The researchers were not able to acquire funding to initiate the study. Also, the study was not approved by the local IRB which requested a FDA new drug application.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-05-15
Primary completion date: 2023-05-15
Completion date: 2023-05-15
Plan to share individual participant data: NO
Clinical trial NCT04675021: Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects
Official title: A Phase I Open-label Study to Assess the Absolute Bioavailability of Savolitinib and Absorption, Distribution, Metabolism, Excretion of [14C]Savolitinib in Healthy Male Subjects
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-13
Primary completion date: 2021-01-11
Completion date: 2021-01-11
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the AZ approved data access tool to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT00352027: Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Official title: Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma
Sponsor: St. Jude Children's Research Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 81.0 (ACTUAL)
Number of arms: 1.0
Start date: 2006-07-20
Primary completion date: 2015-05-31
Completion date: 2022-11-15